NEW YORK&8211;BUSINESS WIRE&8211;Pfizer Inc. NYSE PFE today announced the United States U.S. Food and Drug Administration FDA has approved ABRILADAÂadalimumabafzb as a biosimilar to HumiraÂÂadalimumab1Âfor the treatment of certain patients with rhe...
↧